» Articles » PMID: 10022369

Design and Analysis of Serial Limiting Dilution Assays with Small Sample Sizes

Overview
Publisher Elsevier
Date 1999 Feb 18
PMID 10022369
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

We study the design of serial limiting dilution assays (SLDAs) for estimation of effector cell frequency in settings that restrict severely the amount of material available for assay, and for which the assumption of a single-hit Poisson model is reasonable. For different designs (that is, dilution factor, number of dilution levels, and number of replicates at each level), we evaluate maximum likelihood and minimum chi-square estimators, using four quantitative criteria: probability of a non-informative assay (PNI), bias, coefficient of variation (CV), and mean squared error (MSE). Our results are exact, not simulation-based, nor approximations. We found that differences between these two estimators were insubstantial by comparison with the effect on the estimators of the experimental design. Bias was severe in small assays, and could lead, in extremely small designs, to overestimation of effector frequency by as much as 100%. These four criteria provide a rigorous basis for determining the most effective apportionment of total effort among replicates and dilution levels. By increasing the dilution factor and favoring the number of replicates over the number of dilution levels, the PNI is reduced while bias, CV and MSE are increased; and vice versa. Our study is easily extended to estimation of the density of biologically active particles per volume. It can also be extended to alternatives to the single-hit Poisson model for a serial limiting dilution assay.

Citing Articles

A novel high-throughput microwell outgrowth assay for HIV-infected cells.

Fenton A, Archin N, Turner A, Joseph S, Moeser M, Margolis D J Virol. 2024; 98(3):e0179823.

PMID: 38376258 PMC: 10949454. DOI: 10.1128/jvi.01798-23.


Accuracy of spiked cell counting methods for designing a pre-clinical tumorigenicity study model.

Osada H, Kawatou M, Takeda M, Jo J, Murakami T, Tabata Y Heliyon. 2020; 6(7):e04423.

PMID: 32685738 PMC: 7358391. DOI: 10.1016/j.heliyon.2020.e04423.


A two-stage experimental design for dilution assays.

Ferguson J, Miura T, Miller C Biometrics. 2019; 75(3):1009-1016.

PMID: 30690720 PMC: 7199778. DOI: 10.1111/biom.13032.


HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

Sung J, Patel S, Clohosey M, Roesch L, Tripic T, Kuruc J Mol Ther. 2018; 26(10):2496-2506.

PMID: 30249388 PMC: 6171327. DOI: 10.1016/j.ymthe.2018.08.015.


Development of monoclonal antibodies against axenic amastigotes of strain in Iran: implication for diagnosis of Kala-azar.

Nourizadeh E, Zargar S, Alimohammadian M, Ajdary S, Mahdavi M Iran J Basic Med Sci. 2018; 21(4):388-394.

PMID: 29796222 PMC: 5960755. DOI: 10.22038/IJBMS.2018.25355.6264.